Safe Use of Muscle Relaxants

Introduction to Muscle Relaxant Safety

The American College of Emergency Physicians recommends against co-prescribing multiple muscle relaxants/sedative-hypnotics due to increased toxicity when centrally acting drugs are combined, and specifically lists cyclobenzaprine and methocarbamol as agents that should not be routinely co-prescribed with other sedating medications 1, 2

The American College of Emergency Physicians guidance explicitly lists both cyclobenzaprine and methocarbamol as agents that should not be routinely co-prescribed with other sedating medications, due to increased risk of additive sedation, falls, and injury, particularly in older adults 1, 2
All muscle relaxant trials were 2 weeks or less in duration, indicating these agents should only be used short-term regardless of whether they are combined, according to clinical guidelines 3

The American Geriatrics Society identifies muscle relaxants, including cyclobenzaprine, as potentially inappropriate medications for older adults due to increased risk of anticholinergic effects, sedation, and falls, and recommends alternative approaches 4
If a muscle relaxant is absolutely necessary in an older patient already on one agent, switching rather than adding is the safer approach, to minimize the risk of adverse effects 4

Switch to tizanidine, which has the strongest evidence base as an alternative and works through a different mechanism, if one muscle relaxant is ineffective, according to clinical guidelines 3
Consider that lack of response may indicate the need for a different therapeutic approach rather than adding another sedating agent, to minimize the risk of adverse effects 3

The FDA has issued a warning about combining sedating medications, particularly opioids and benzodiazepines, due to the risk of respiratory depression and death, highlighting the importance of cautious prescribing practices for muscle relaxants like cyclobenzaprine and methocarbamol 5

In patients with hepatic impairment, cyclobenzaprine's AUC and Cmax are approximately double, necessitating cautious use, starting with 5 mg and titrating slowly, while methocarbamol has significantly impaired elimination in liver disease, although no specific citation is provided for methocarbamol's impairment, the context of cyclobenzaprine's caution is relevant 5

In patients receiving chronic opioid therapy, tolerance to opioid‑induced respiratory depression develops rapidly, but this protective tolerance does not apply to non‑opioid central nervous system depressants such as cyclobenzaprine, which adds an independent mechanism of respiratory and CNS depression. This conclusion is based on data reported in the Annals of Internal Medicine (2006)【6】【7】.